Consolidated Financial Statement Details (Tables)

12 Months Ended

Dec. 31, 2023

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory

Inventory consists of the following (in thousands):

	December 31,
	2023		2022
Raw materials	$	1,861	$	2,575
Work-in-process		12,880		10,749
Finished goods		1,360		5,878
Total inventory	$	16,101	$	19,202

Schedule of Other Current Assets

Other Current Assets

Other current assets consists of the following (in thousands):

	December 31,
	2023		2022
Prepaid research and development expenses	$	4,325	$	7,398
Non-trade receivables and other		1,047		2,423
Other prepaid expenses		4,407		5,987
Total other current assets	$	9,779	$	15,808

Schedule of Property, Plant and Equipment

Property, Plant and Equipment

Property, plant and equipment consists of the following (in thousands):

	December 31,
	2023			2022
Building and leasehold improvements	$	43,184		$	74,889
Laboratory equipment		14,537			24,243
Computer equipment and software		22,438			26,205
Manufacturing equipment		24,315			25,052
Furniture, fixtures, and other		541			4,263
Depreciable property, plant and equipment at cost		105,015			154,652
Less: accumulated depreciation		(86,898	)		(124,731	)
Depreciable property, plant and equipment, net		18,117			29,921
Construction-in-progress		739			2,530
Property, plant and equipment, net	$	18,856		$	32,451

We recorded the gains and losses as follows (in thousands):

	Year Ended December 31,
	2023		2022
Proceeds from sales	$	1,245	$	13,196
Net book value of assets		2,545		9,870
Total (gain) loss on sale or disposal of other property, plant and equipment, net	$	1,300	$	(3,326	)

Schedule of Goodwill

Goodwill

The following is a reconciliation of the change in our goodwill for the year ended December 31, 2023 (in thousands):

	Year Ended December 31, 2023
Goodwill – beginning balance	$	76,501
Impairment of goodwill		(76,501	)
Goodwill – ending balance	$	—

Schedule of Accred Expenses

Accrued Expenses

Accrued expenses consist of the following (in thousands):

	December 31,
	2023		2022
Accrued compensation	$	5,553	$	9,582
Accrued clinical trial expenses		4,321		12,262
Liability to collaboration partners		2,678		3,808
Accrued contract termination costs		3,020		3,902
Other accrued expenses		6,590		7,003
Total accrued expenses	$	22,162	$	36,557

Schedule of Accumulated Other Comprehensive Income (Loss)

Accumulated Other Comprehensive Income (Loss)

The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands):

	Foreign currency translation			Available-for-sale securities			Accumulated Other Comprehensive Income
Balance at December 31, 2022	$	(5,131	)	$	(1,776	)	$	(6,907	)
Foreign currency translation gain		62			—			62
Unrealized gain on available-for-sale securities		—			1,826			1,826
Reclassification adjustments to income		5,099			—			5,099
Balance at December 31, 2023	$	30		$	50		$	80